Pan-cancer research, however, found that TMB could only serve as an ICI response efficacy predictor when CD8+ T cells were positively associated with neoantigen load, which correlated positively with TMB, including melanoma and lung cancers, but not that of head and neck cancers (8), yet their HPV status were not clarified. This evidence concerns the gene CD8A and head and neck cancer.